COTEMPLA XR-ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COTEMPLA XR-ODT (COTEMPLA XR-ODT).
COTEMPLA XR-ODT contains methylphenidate, a central nervous system stimulant. The mechanism of action is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the extraneuronal space. This leads to stimulant effects on the CNS and increased attention and focus.
| Metabolism | Methylphenidate is extensively metabolized primarily by de-esterification to the inactive metabolite ritalinic acid (α-phenyl-2-piperidine acetic acid). The de-esterification is mediated by carboxylesterase 1A1 (CES1A1) and carboxylesterase 1A2 (CES1A2). Minor pathways include hydroxylation and microsomal oxidation. |
| Excretion | Renal: 78% (as unchanged methylphenidate), Fecal/Biliary: minimal |
| Half-life | 6-8 h (terminal half-life of extended-release formulation; reflects slow absorption phase) |
| Protein binding | 10-33% (primarily albumin) |
| Volume of Distribution | 2.65 L/kg (indicates extensive tissue distribution) |
| Bioavailability | 22-25% (extensive first-pass metabolism; absolute bioavailability of oral methylphenidate) |
| Onset of Action | Orally disintegrating tablet: 1-2 h |
| Duration of Action | 12 h (maintained plasma levels throughout the day) |
Initial: 17.3 mg orally once daily, may increase to 34.6 mg once daily after 1 week. Maximum: 34.6 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: No adjustment; GFR <30 mL/min: Avoid use. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose to 17.3 mg once daily; Child-Pugh C: Avoid use. |
| Pediatric use | Approved for ages 6-17 years. Weight <34 kg: 17.3 mg once daily; Weight ≥34 kg: 17.3-34.6 mg once daily. |
| Geriatric use | Not recommended for patients aged ≥65 years due to lack of safety and efficacy data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COTEMPLA XR-ODT (COTEMPLA XR-ODT).
| Breastfeeding | Methylphenidate is excreted into breast milk; the milk-to-plasma ratio (M/P) is approximately 2.7. Relative infant dose is estimated to be up to 2.1% of the maternal weight-adjusted dose. Limited data on long-term effects; caution advised due to potential for CNS stimulation in the infant. Consider monitoring for agitation, insomnia, and poor feeding. |
| Teratogenic Risk | First trimester: Studies show increased risk of major congenital malformations, particularly cardiac anomalies and oral clefts, with first-trimester exposure. Second and third trimesters: Associated with preterm birth, low birth weight, and neonatal withdrawal (irritability, hypertonia, feeding difficulties). Chronic exposure may lead to neonatal toxicity and growth restriction. |
■ FDA Black Box Warning
WARNING: ABUSE, MISUSE, AND ADDICTION. COTEMPLA XR-ODT has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse or abuse can cause serious cardiovascular adverse events and sudden death. Assess each patient’s risk for abuse, misuse, and addiction before prescribing and monitor regularly.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI","Glaucoma","Marked anxiety, tension, or agitation","Patients with a history of drug abuse or dependence"]
| Precautions | ["Serious cardiovascular events: Use caution in patients with structural cardiac abnormalities or other serious heart problems; avoid in known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems.","Increased blood pressure and heart rate: Monitor regularly.","Psychiatric adverse reactions: May cause treatment-emergent psychotic or manic symptoms; caution in patients with pre-existing psychosis or bipolar disorder.","Seizures: Use with caution in patients with a history of seizures.","Priapism: If painful or prolonged erections occur, seek immediate medical attention.","Peripheral vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.","Long-term suppression of growth: Monitor height and weight during treatment."] |
Loading safety data…
| Fetal Monitoring | Maternal: Regular monitoring of blood pressure, heart rate, and weight gain; assess for signs of tolerance, dependence, or adverse effects. Fetal: Ultrasound for fetal growth and anatomy; consider fetal echocardiography if first-trimester exposure. Neonatal: Observe for withdrawal symptoms (irritability, hypertonia) and provide supportive care if needed. |
| Fertility Effects | In animal studies, methylphenidate has been associated with reduced fertility and spermatogenesis. In humans, limited data suggest potential for reversible effects on male fertility (sperm count and motility) with long-term use. No well-documented effects on female fertility. |
| Food/Dietary | No specific food interactions noted; may be taken with or without food. High-fat meals may delay absorption but not overall extent. Avoid alcohol as it can cause dose dumping. |
| Clinical Pearls | COTEMPLA XR-ODT is a long-acting methylphenidate formulation for ADHD; do not crush or chew; administer with or without food; avoid alcohol due to potential for dose dumping. Monitor for growth suppression, blood pressure, and psychiatric effects. Use with caution in patients with seizures, tics, or glaucoma. |
| Patient Advice | Take exactly as prescribed; do not crush, chew, or split the tablet. · Administer once daily in the morning; avoid afternoon or evening doses to prevent insomnia. · Store at room temperature away from moisture and heat. · Avoid alcohol while taking this medication. · Report any chest pain, shortness of breath, or signs of serotonin syndrome. · Regular blood pressure and heart rate monitoring is necessary. · Potential for dependence; do not share medication. |